The Asymmetric Trap Hidden in Mirum Pharmaceuticals (MIRM)

The Surface Narrative Is a Distraction

If you only read the financial headlines, Mirum Pharmaceuticals (MIRM) looks like a standard biotech momentum play that has already run its course. Up an impressive 128% over the past year, the stock recently cooled off from its February highs above $108, drifting down to the $92 level. The retail consensus assumes the upside is fully priced in and the trade is over.

But when you strip away the noise and dig into the market microstructure, a completely different reality emerges. A massive, structural tension is building beneath the surface. We have a company printing undeniable fundamental growth, yet attracting a staggering amount of short interest. The smart money is quietly hoarding shares while the crowd is busy buying puts. This is the exact kind of mathematical and psychological setup that precedes a violent repricing.

Unprecedented Growth Meets Baffling Pessimism

Let’s look at the actual cash generation. This is not your typical cash-burning biotech selling a distant dream. Mirum’s revenue growth is explosive and tangible. Total revenue in Q4 2024 was $99.4 million. By Q4 2025, it had scaled to $148.9 million. Their leading asset, LIVMARLI, is dominating its niche, and their bile acid medicines are expanding rapidly. The company is operating with over $298 million in cash and equivalents as of the end of 2025, rendering immediate dilution risks virtually non-existent.

Yet, the short interest sits at an eye-watering 20.12% of the float—over 8.2 million shares sold short. Why are funds so aggressively betting against a company with a vertically scaling top line?

The fear seemed to be centered around upcoming clinical trial risks, but that thesis just evaporated. On April 27, Mirum announced incredibly positive Phase 2b topline results for brelovitug in chronic hepatitis delta virus (HDV). The trial met its primary endpoint at Week 24 with highly significant efficacy and zero treatment-related serious adverse events.

While the shorts have been doubling down, the titans of Wall Street are accumulating. Janus Henderson increased its stake to 11.8% earlier this year. And exactly coinciding with the Phase 2b data on April 27, BlackRock filed a Schedule 13G/A revealing a massive new 5.7% stake (3.46 million shares). The "smart money" is actively buying the exact shares the short sellers are borrowing.

The Options Market Smells Blood

The derivatives market is showing classic signs of stress and dislocation. If we look at the options summary, the Put/Call Open Interest ratio was a complacent 0.07 back on April 1. By April 27, it had ballooned to 1.17. Abnormal options volume triggered repeatedly in mid-April.

The street is aggressively hedging. Traditional technical analysis algorithms even flashed a "dead cross above zero" on April 22, triggering automated sell programs. The micro-state of the stock shifted to a "potential bear" scenario over the last few trading days. This is creating a perfect illusion of weakness—a technical bear trap designed to provide liquidity for institutional buyers to fill their massive orders.

Decoding the Dark Pools and Microstructure

When we examine the dark pools and off-exchange activity, a fascinating narrative emerges. We must look at the interplay between the TRF ratio, the off-exchange short percentage, the volume Z-score, and the rolling close location value to uncover hidden institutional accumulation and potential volume-price divergence. Historically, when the TRF ratio and volume Z-score hit recent extremes on the same day, it acts as a precursor to a new trend. On April 21, the TRF ratio and the off-exchange short percentage both hit extreme peak percentiles (1.000), while the rolling close location value cratered to a dismal 0.147, indicating severe off-exchange shorting driving the daily close near the lows. However, the very next day, April 22, the volume Z-score spiked to a high of 1.298 while the TRF ratio collapsed to an extreme low of 0.017, and the rolling close location value violently reversed to 0.929. This precise structural anomaly—massive off-exchange shorting immediately followed by an aggressive on-exchange volume surge that closes the stock at the absolute highs—screams of a bearish trap. The off-exchange short percentage remained elevated, but the shifting rolling close location value confirms that the intraday multi-day trend has flipped from bearish distribution to aggressive institutional absorption. This divergence was the silent tell, front-running the positive Phase 2b data and BlackRock's massive 13G/A filing days later.

The Imminent Squeeze: The May Earnings Catalyst

We are now looking at a ticking time bomb. The Phase 2b AZURE-1 HDV data catalyst has already proven the pipeline's viability. If you look at recent insider activity, executives like the CEO and COO have been selling small fractions strictly to cover tax withholding obligations on vested RSUs—standard bureaucratic mechanics, not a loss of faith.

With the next earnings report scheduled for May 6, 2026, the setup is wildly asymmetric. You have over 20% of the float short in a company where BlackRock, Janus Henderson, and Eventide are aggressively locking up the supply. You have dark pool data screaming that institutional accumulation just trapped a massive off-exchange shorting operation. You have climbing options pessimism masking fundamentally stellar revenue growth.

When the broader market finally reconciles Mirum's financial reality with this artificially depressed microstructure, the repricing will not be polite. The shorts are trapped in a crowded theater, and the institutions just quietly locked the exit.